Novo Nordisk shares crashed over 15% on Monday after its next-generation weight loss drug CagriSema failed to match Eli Lilly's tirzepatide (sold as Zepbound) in the pivotal REDEFINE 4 trial. Over 84 weeks, CagriSema delivered 20.2% weight loss compared to 23.6% for tirzepatide — a 3.4-percentage-point gap that was statistically significant, meaning the drug failed its primary endpoint of non-inferiority.
The result is a major blow to Novo Nordisk, which had pinned its competitive strategy on CagriSema — a combination of semaglutide and cagrilintide — to reclaim ground in the booming obesity drug market. Eli Lilly shares rose 4% on the news, further cementing its dominance. Novo filed CagriSema for FDA approval late last year, with a decision expected by late 2026, but the failed trial raises questions about its commercial positioning.
